About Orchid Pharma Limited
Data last updated: 15 December 2025
Orchid Pharma Limited is a public limited company based in Chengalpattu, Tamil Nadu, India, a subsidiary of Dhanuka Laboratories Limited. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 July 1992, the company has been in operation for over 34 years.
Registered with ROC Chennai under CIN L24222TN1992PLC022994. Listed on BSE: 524372 and NSE: BE : ORCHPHARMA.
Capital: an authorised share capital of ₹150 Cr and a paid-up capital of ₹50.72 Cr. Formerly known as Orchid Chemicals & Pharmaceuticals Limited. It is led by directors including Mridul Dhanuka and Arjun Dhanuka.
Last AGM: 20 September 2025. Financial statements filed for year ended 31 March 2025. Office: Plot No 121 – 128 128A – 133 138 – 151 159 – 164, Sidco Industrial Estate Alathur Chengalpattu, Tamil Nadu, India – 603110.
As per the financials filed for FY 2025, the company reported a revenue of ₹949.4 Cr, a growth of 12% compared to the previous year.
The company has a workforce of approximately 1,101 employees as per the latest available data. It operates as a subsidiary of Dhanuka Laboratories Limited. Its group structure includes 1 subsidiary.
The company is associated with 1 brand - Orchid Pharma. As per MCA filings, the company has open charges of ₹366.5 Cr and satisfied charges of ₹15,354 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website orchidpharma.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media**************
-
Registered AddressPlot No 121 – 128 128A – 133 138 – 151 159 – 164, Sidco Industrial Estate Alathur Chengalpattu, Tamil Nadu, India – 603110
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Orchid Pharma Limited
Orchid Pharma Limited has one previous CIN (Corporate Identification Number): U24222TN1992PLC022994. The current CIN is L24222TN1992PLC022994, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24222TN1992PLC022994 | Current |
| U24222TN1992PLC022994 | Previous |
Associated Brands with Orchid Pharma Limited
Orchid Pharma Limited operates one associated brand: Orchid Pharma. These brands represent Orchid Pharma Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Bulk actives, formulations, and nutraceuticals are developed and manufactured. | orchidpharma.com |
Business Activity of Orchid Pharma Limited
Orchid Pharma Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | ********* |
Auditor Details of Orchid Pharma Limited
Orchid Pharma Limited is audited by Singhi and Co. (ICAI peer reviewed, certificate valid till 2028-08-31) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Singhi and Co. (ICAI peer reviewed, certificate valid till 2028-08-31) | FY 2026 | Statement on impact of audit qualification |
Board of Directors of Orchid Pharma Limited
Orchid Pharma Limited is currently managed by 10 directors, with 40 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Mridul Dhanuka
Also directs:
Dhanuka Laboratories Limited, Orbion Pharmaceuticals Private Limited, Orchid Bio-Pharma Limited and 1 more
|
Whole-Time Director | 31 Mar 2020 | 6 Years 3 Months | Current |
|
Arjun Dhanuka
Also directs:
Dhanuka Laboratories Limited
|
Director | 20 Oct 2023 | 2 Years 8 Months | Current |
| Tanu Singla | Director | 29 Jun 2020 | 6 Years 0 Months | Current |
| Dharam Vir | Director | 29 Jun 2020 | 6 Years 0 Months | Current |
|
Manish Dhanuka
Also directs:
Dhanuka Laboratories Limited, Orchid Bio-Pharma Limited, Dhanuka Agritech Limited and 2 more
|
Managing Director | 31 Mar 2020 | 6 Years 3 Months | Current |
|
Shubha Singh
Also directs:
Lords Chloro Alkali Limited, Amd Industries Limited, Jubilant Bevco Limited and 5 more
|
Director | 23 May 2024 | 2 Years 1 Months | Current |
Financials of Orchid Pharma Limited FY 2026 filings available
Orchid Pharma Limited reported revenue of ₹811.33 Cr (down 12% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹811.33 Cr | ₹921.93 Cr | ₹819.37 Cr | ₹665.9 Cr | ₹559.56 Cr | ₹450.06 Cr | ₹508.04 Cr |
| Other Income | ₹35.17 Cr | ₹27.47 Cr | ₹30.86 Cr | ₹19.43 Cr | ₹9 Cr | ₹15.23 Cr | ₹24.49 Cr |
| Total Income | ₹846.5 Cr | ₹949.4 Cr | ₹850.23 Cr | ₹685.33 Cr | ₹568.56 Cr | ₹465.29 Cr | ₹532.53 Cr |
| Cost of Materials Consumed | ₹462.34 Cr | ₹585.46 Cr | ₹528.35 Cr | ₹406.1 Cr | ₹340.62 Cr | ₹245.6 Cr | ₹235.54 Cr |
| Purchases of Stock-in-Trade | ₹1.69 Cr | ₹2.61 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹16.68 Lakh |
| Changes in Inventories | ₹61.85 Cr | -₹43.85 Cr | -₹43.89 Cr | -₹21.48 Cr | -₹27.06 Cr | -₹17.09 Cr | ₹7.58 Cr |
| Employee Benefit Expense | ₹91.47 Cr | ₹86.36 Cr | ₹69.64 Cr | ₹65.35 Cr | ₹63.28 Cr | ₹67.11 Cr | ₹84.75 Cr |
| Finance Costs | ₹13.26 Cr | ₹14.54 Cr | ₹16.35 Cr | ₹32.23 Cr | ₹32.01 Cr | ₹51.34 Cr | ₹4.16 Cr |
| Depreciation & Amortisation | ₹35.45 Cr | ₹34.55 Cr | ₹33.24 Cr | ₹54.79 Cr | ₹87.02 Cr | ₹108.92 Cr | ₹125.92 Cr |
| Other Expenses | ₹152.85 Cr | ₹174.17 Cr | ₹154.59 Cr | ₹132.31 Cr | ₹133.11 Cr | ₹104.67 Cr | ₹205.49 Cr |
| Total Expenses | ₹818.91 Cr | ₹853.84 Cr | ₹758.29 Cr | ₹669.29 Cr | ₹628.98 Cr | ₹560.54 Cr | ₹663.6 Cr |
| Profit Before Exceptional Items & Tax | ₹27.59 Cr | ₹95.56 Cr | ₹91.95 Cr | ₹16.04 Cr | -₹60.42 Cr | -₹95.25 Cr | -₹131.07 Cr |
| Exceptional Items | -₹6.57 Cr | ₹0 | ₹0 | ₹39.21 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹21.02 Cr | ₹95.56 Cr | ₹91.95 Cr | ₹55.25 Cr | -₹60.42 Cr | -₹95.25 Cr | -₹131.07 Cr |
| Total Tax Expense | -₹19.16 Lakh | -₹19.35 Lakh | -₹3.12 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹20.55 Cr | ₹99.66 Cr | ₹92.17 Cr | ₹46.32 Cr | -₹1.95 Cr | -₹116.53 Cr | -₹131.07 Cr |
| attributable to Owners | - | - | - | ₹0 | ₹0 | - | - |
| attributable to NCI | - | - | - | ₹0 | ₹0 | - | - |
| Other Comprehensive Income | ₹89.69 Lakh | -₹75.13 Lakh | -₹33.72 Lakh | -₹17.88 Lakh | ₹1.42 Cr | ₹66.47 Lakh | -₹2.02 Cr |
| Total Comprehensive Income | ₹21.44 Cr | ₹98.91 Cr | ₹91.83 Cr | ₹46.14 Cr | -₹52.82 Lakh | -₹115.87 Cr | -₹133.09 Cr |
| EBITDA (computed) | ₹76.3 Cr | ₹144.65 Cr | ₹141.54 Cr | ₹103.05 Cr | ₹58.61 Cr | ₹65 Cr | -₹99.04 Lakh |
| Basic EPS | ₹4.05 | ₹19.65 | ₹19.06 | ₹13.01 | ₹-0.48 | ₹-28.55 | ₹-32.11 |
| Diluted EPS | ₹4.05 | ₹19.65 | ₹19.06 | ₹13.01 | ₹-0.48 | ₹-28.55 | ₹-32.11 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,910.91 Cr | ₹1,687.91 Cr | ₹1,553.87 Cr | ₹1,225.21 Cr |
| Non-current Assets | ₹1,227.01 Cr | ₹880.5 Cr | ₹763.12 Cr | ₹724.2 Cr |
| Current Assets | ₹683.61 Cr | ₹807.42 Cr | ₹790.75 Cr | ₹501.01 Cr |
| Property, Plant & Equipment | ₹613.22 Cr | ₹631.59 Cr | ₹618.92 Cr | ₹572.71 Cr |
| Inventories | ₹256.41 Cr | ₹326.37 Cr | ₹264.23 Cr | ₹228.74 Cr |
| Trade Receivables | ₹263.87 Cr | ₹241.83 Cr | ₹195.55 Cr | ₹215.19 Cr |
| Cash & Equivalents | ₹7.01 Cr | ₹21.11 Cr | ₹3.6 Cr | ₹22.6 Cr |
| Equity (Net Worth) | ₹1,287.79 Cr | ₹1,267.29 Cr | ₹1,169.47 Cr | ₹688.65 Cr |
| Equity Share Capital | ₹50.72 Cr | ₹50.72 Cr | ₹50.72 Cr | ₹40.82 Cr |
| Borrowings (Non-current) | ₹327.73 Cr | ₹131.64 Cr | ₹120.43 Cr | ₹148.84 Cr |
| Borrowings (Current) | ₹29.75 Cr | ₹42.6 Cr | ₹14.05 Cr | ₹182.51 Cr |
| Total Debt (computed) | ₹357.48 Cr | ₹174.24 Cr | ₹134.48 Cr | ₹331.35 Cr |
| Current Liabilities | ₹278.97 Cr | ₹285.57 Cr | ₹259.97 Cr | ₹371.89 Cr |
| Total Liabilities | ₹623.13 Cr | ₹420.63 Cr | ₹384.41 Cr | ₹536.56 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹101.2 Cr | ₹19.22 Cr | ₹125.99 Cr | ₹18.58 Cr | ₹88.95 Cr |
| Investing Cash Flow | -₹285.27 Cr | -₹26.93 Cr | -₹312.03 Cr | -₹31.46 Cr | ₹116.46 Cr |
| Financing Cash Flow | ₹169.98 Cr | ₹25.22 Cr | ₹167.04 Cr | ₹31.17 Cr | -₹216.8 Cr |
| Capital Expenditure | ₹383.58 Cr | ₹150.11 Cr | -₹64.81 Cr | ₹84.91 Cr | ₹14.4 Cr |
| Free Cash Flow (computed) | -₹282.39 Cr | -₹130.89 Cr | ₹61.18 Cr | -₹66.33 Cr | ₹74.55 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹14.1 Cr | ₹17.51 Cr | -₹19 Cr | ₹18.29 Cr | -₹11.39 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹237.61 Cr | ₹207.27 Cr | ₹193.52 Cr | ₹172.93 Cr | ₹237.48 Cr | ₹217.34 Cr | ₹222.7 Cr | ₹244.41 Cr | ₹217.1 Cr | ₹220.59 Cr | ₹198.76 Cr | ₹182.92 Cr |
| Other Income | ₹7.34 Cr | ₹5.61 Cr | ₹10.77 Cr | ₹11.45 Cr | ₹3.9 Cr | ₹8.49 Cr | ₹7.52 Cr | ₹7.57 Cr | ₹13.36 Cr | ₹7.62 Cr | ₹8.36 Cr | ₹1.89 Cr |
| Total Income | ₹244.95 Cr | ₹212.88 Cr | ₹204.3 Cr | ₹184.38 Cr | ₹241.38 Cr | ₹225.83 Cr | ₹230.22 Cr | ₹251.98 Cr | ₹230.46 Cr | ₹228.21 Cr | ₹207.11 Cr | ₹184.81 Cr |
| Cost of Materials Consumed | ₹120.95 Cr | ₹118.97 Cr | ₹112.27 Cr | ₹110.16 Cr | ₹136.94 Cr | ₹142.02 Cr | ₹153.72 Cr | ₹152.77 Cr | ₹156.47 Cr | ₹135.62 Cr | ₹117.86 Cr | ₹118.41 Cr |
| Purchases of Stock-in-Trade | ₹47.59 Lakh | ₹25 Lakh | ₹17.34 Lakh | ₹78.79 Lakh | ₹1.24 Cr | ₹1.37 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹29.93 Cr | ₹23.93 Cr | ₹20.07 Cr | -₹12.08 Cr | -₹17.24 Lakh | -₹18.6 Cr | -₹22.56 Cr | -₹2.52 Cr | -₹28.34 Cr | -₹13.68 Cr | ₹4.47 Cr | -₹6.34 Cr |
| Employee Benefit Expense | ₹20.88 Cr | ₹24.13 Cr | ₹24.85 Cr | ₹21.61 Cr | ₹22.24 Cr | ₹22.06 Cr | ₹20.06 Cr | ₹22 Cr | ₹17.57 Cr | ₹19.14 Cr | ₹17.56 Cr | ₹16.22 Cr |
| Finance Costs | ₹3.09 Cr | ₹3.18 Cr | ₹3.73 Cr | ₹3.26 Cr | ₹3.92 Cr | ₹3.8 Cr | ₹3.33 Cr | ₹3.5 Cr | ₹3.47 Cr | ₹3.54 Cr | ₹3.8 Cr | ₹5.55 Cr |
| Depreciation & Amortisation | ₹8.87 Cr | ₹9.03 Cr | ₹8.9 Cr | ₹8.65 Cr | ₹8.87 Cr | ₹8.61 Cr | ₹8.63 Cr | ₹8.44 Cr | ₹8.42 Cr | ₹9.27 Cr | ₹7.84 Cr | ₹7.71 Cr |
| Other Expenses | ₹38.51 Cr | ₹38.43 Cr | ₹37.64 Cr | ₹38.28 Cr | ₹49.24 Cr | ₹44.13 Cr | ₹41.14 Cr | ₹39.66 Cr | ₹42.49 Cr | ₹44.12 Cr | ₹35.55 Cr | ₹32.49 Cr |
| Total Expenses | ₹222.7 Cr | ₹217.91 Cr | ₹207.63 Cr | ₹170.67 Cr | ₹222.28 Cr | ₹203.38 Cr | ₹204.32 Cr | ₹223.86 Cr | ₹200.08 Cr | ₹198.01 Cr | ₹187.09 Cr | ₹174.03 Cr |
| Profit Before Exceptional Items & Tax | ₹22.25 Cr | -₹5.03 Cr | -₹3.33 Cr | ₹13.71 Cr | ₹19.09 Cr | ₹22.45 Cr | ₹25.9 Cr | ₹28.12 Cr | ₹30.38 Cr | ₹30.19 Cr | ₹20.02 Cr | ₹10.78 Cr |
| Exceptional Items | ₹53.92 Lakh | -₹7.11 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹22.79 Cr | -₹12.15 Cr | -₹3.33 Cr | ₹13.71 Cr | ₹19.09 Cr | ₹22.45 Cr | ₹25.9 Cr | ₹28.12 Cr | ₹30.38 Cr | ₹30.19 Cr | ₹20.02 Cr | ₹10.78 Cr |
| Total Tax Expense | ₹17,000 | ₹0 | ₹0 | ₹0 | -₹3.94 Lakh | ₹0 | ₹0 | -₹15.41 Lakh | -₹3.12 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹23.78 Cr | -₹12.61 Cr | -₹5.72 Cr | ₹14.91 Cr | ₹22.29 Cr | ₹20.78 Cr | ₹27.24 Cr | ₹29.35 Cr | ₹32.96 Cr | ₹29.43 Cr | ₹19.8 Cr | ₹9.4 Cr |
| attributable to Owners | - | - | - | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| attributable to NCI | - | - | - | ₹0 | - | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹88.2 Lakh | ₹56.42 Lakh | -₹39.45 Lakh | -₹15.48 Lakh | ₹1.67 Cr | -₹80.14 Lakh | -₹1.49 Cr | -₹12.44 Lakh | ₹1.6 Cr | -₹64.7 Lakh | -₹1.24 Cr | -₹5.82 Lakh |
| Total Comprehensive Income | ₹24.66 Cr | -₹12.05 Cr | -₹6.12 Cr | ₹14.76 Cr | ₹23.96 Cr | ₹19.97 Cr | ₹25.74 Cr | ₹29.23 Cr | ₹34.56 Cr | ₹28.78 Cr | ₹18.57 Cr | ₹9.35 Cr |
| EBITDA (computed) | ₹34.21 Cr | ₹7.17 Cr | ₹9.3 Cr | ₹25.62 Cr | ₹31.88 Cr | ₹34.85 Cr | ₹37.85 Cr | ₹40.06 Cr | ₹42.28 Cr | ₹43.01 Cr | ₹31.67 Cr | ₹24.03 Cr |
| Basic EPS | ₹4.69 | ₹-2.49 | ₹-1.13 | ₹2.94 | ₹4.40 | ₹4.10 | ₹5.37 | ₹5.79 | ₹6.81 | ₹6.18 | ₹4.30 | ₹1.85 |
| Diluted EPS | ₹4.69 | ₹-2.49 | ₹-1.13 | ₹2.94 | ₹4.40 | ₹4.10 | ₹5.37 | ₹5.79 | ₹6.81 | ₹6.18 | ₹4.30 | ₹1.85 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹811.33 Cr | ₹921.93 Cr | ₹819.37 Cr | ₹665.9 Cr | ₹556.97 Cr | ₹450.7 Cr | ₹505.45 Cr |
| Other Income | ₹55.24 Cr | ₹31.93 Cr | ₹30.39 Cr | ₹19.43 Cr | ₹9 Cr | ₹6.48 Cr | ₹24.49 Cr |
| Total Income | ₹866.57 Cr | ₹953.86 Cr | ₹849.76 Cr | ₹685.33 Cr | ₹565.98 Cr | ₹457.17 Cr | ₹529.94 Cr |
| Cost of Materials Consumed | ₹462.34 Cr | ₹585.46 Cr | ₹528.35 Cr | ₹406.1 Cr | ₹336.8 Cr | ₹244.96 Cr | ₹234.24 Cr |
| Purchases of Stock-in-Trade | ₹1.69 Cr | ₹2.61 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹16.68 Lakh |
| Changes in Inventories | ₹61.85 Cr | -₹43.85 Cr | -₹43.89 Cr | -₹21.48 Cr | -₹22.73 Cr | -₹15.69 Cr | ₹5.83 Cr |
| Employee Benefit Expense | ₹88.14 Cr | ₹86.36 Cr | ₹69.64 Cr | ₹65.35 Cr | ₹60.21 Cr | ₹64.4 Cr | ₹81.48 Cr |
| Finance Costs | ₹13.24 Cr | ₹14.54 Cr | ₹16.33 Cr | ₹32.23 Cr | ₹32.01 Cr | ₹51.34 Cr | ₹4.16 Cr |
| Depreciation & Amortisation | ₹35.56 Cr | ₹34.44 Cr | ₹33.22 Cr | ₹54.79 Cr | ₹87.02 Cr | ₹108.9 Cr | ₹125.9 Cr |
| Other Expenses | ₹151.98 Cr | ₹167.81 Cr | ₹154.59 Cr | ₹132.31 Cr | ₹125.44 Cr | ₹99.14 Cr | ₹227.99 Cr |
| Total Expenses | ₹814.79 Cr | ₹847.37 Cr | ₹758.23 Cr | ₹669.29 Cr | ₹618.75 Cr | ₹553.04 Cr | ₹679.77 Cr |
| Profit Before Exceptional Items & Tax | ₹51.78 Cr | ₹106.48 Cr | ₹91.52 Cr | ₹16.04 Cr | -₹52.77 Cr | -₹95.87 Cr | -₹149.84 Cr |
| Exceptional Items | -₹6.57 Cr | ₹0 | ₹0 | ₹39.21 Cr | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹45.21 Cr | ₹106.48 Cr | ₹91.52 Cr | ₹55.25 Cr | -₹52.77 Cr | -₹95.87 Cr | -₹149.84 Cr |
| Total Tax Expense | ₹0 | ₹0 | -₹3.23 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹45.21 Cr | ₹106.48 Cr | ₹94.75 Cr | ₹54.19 Cr | -₹4.81 Cr | -₹117.15 Cr | -₹149.84 Cr |
| Other Comprehensive Income | ₹89.69 Lakh | -₹75.13 Lakh | -₹33.72 Lakh | -₹17.88 Lakh | ₹1.42 Cr | ₹66.47 Lakh | -₹2.02 Cr |
| Total Comprehensive Income | ₹46.1 Cr | ₹105.73 Cr | ₹94.41 Cr | ₹54.01 Cr | -₹3.38 Cr | -₹116.49 Cr | -₹151.86 Cr |
| EBITDA (computed) | ₹100.58 Cr | ₹155.46 Cr | ₹141.07 Cr | ₹103.05 Cr | ₹66.26 Cr | ₹64.36 Cr | -₹19.78 Cr |
| Basic EPS | ₹8.91 | ₹20.99 | ₹19.59 | ₹13.54 | ₹-1.18 | ₹-28.70 | ₹-36.71 |
| Diluted EPS | ₹8.91 | ₹20.99 | ₹19.59 | ₹13.54 | ₹-1.18 | ₹-28.70 | ₹-36.71 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Total Assets | ₹1,750.12 Cr | ₹1,696.58 Cr | ₹1,552.2 Cr | ₹1,223.26 Cr |
| Non-current Assets | ₹1,114.13 Cr | ₹910.19 Cr | ₹769.91 Cr | ₹729.46 Cr |
| Current Assets | ₹635.99 Cr | ₹786.39 Cr | ₹782.29 Cr | ₹493.79 Cr |
| Property, Plant & Equipment | ₹591.69 Cr | ₹612.12 Cr | ₹615.12 Cr | ₹572.67 Cr |
| Inventories | ₹256.41 Cr | ₹326.37 Cr | ₹264.23 Cr | ₹228.74 Cr |
| Trade Receivables | ₹263.87 Cr | ₹241.83 Cr | ₹189.37 Cr | ₹211.91 Cr |
| Cash & Equivalents | ₹1.24 Cr | ₹15.87 Cr | ₹29.47 Lakh | ₹18.31 Cr |
| Equity (Net Worth) | ₹1,370.15 Cr | ₹1,324.05 Cr | ₹1,218.32 Cr | ₹731.96 Cr |
| Equity Share Capital | ₹50.72 Cr | ₹50.72 Cr | ₹50.72 Cr | ₹40.82 Cr |
| Borrowings (Non-current) | ₹178.62 Cr | ₹131.64 Cr | ₹120.21 Cr | ₹148.84 Cr |
| Borrowings (Current) | ₹95.81 Lakh | ₹42.6 Cr | ₹14.05 Cr | ₹182.51 Cr |
| Total Debt (computed) | ₹179.58 Cr | ₹174.24 Cr | ₹134.26 Cr | ₹331.35 Cr |
| Current Liabilities | ₹182.8 Cr | ₹237.47 Cr | ₹209.67 Cr | ₹326.63 Cr |
| Total Liabilities | ₹379.96 Cr | ₹372.53 Cr | ₹333.89 Cr | ₹491.3 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹118.64 Cr | ₹27.48 Cr | ₹130.73 Cr | ₹13.39 Cr | ₹89.57 Cr |
| Investing Cash Flow | -₹125.37 Cr | -₹37.35 Cr | -₹315.81 Cr | -₹26.7 Cr | ₹112.93 Cr |
| Financing Cash Flow | -₹7.9 Cr | ₹25.44 Cr | ₹167.07 Cr | ₹31.17 Cr | -₹216.8 Cr |
| Capital Expenditure | ₹165.77 Cr | ₹68.54 Cr | ₹55.15 Cr | ₹84.55 Cr | ₹14.4 Cr |
| Free Cash Flow (computed) | -₹47.13 Cr | -₹41.06 Cr | ₹75.57 Cr | -₹71.16 Cr | ₹75.16 Cr |
| Dividends Paid | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Net Change in Cash | -₹14.63 Cr | ₹15.58 Cr | -₹18.01 Cr | ₹17.86 Cr | -₹14.3 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 | Q3 FY24 | Q2 FY24 | Q1 FY24 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹237.61 Cr | ₹207.27 Cr | ₹193.52 Cr | ₹172.93 Cr | ₹237.48 Cr | ₹217.34 Cr | ₹222.7 Cr | ₹244.41 Cr | ₹217.1 Cr | ₹220.59 Cr | ₹198.76 Cr | ₹182.92 Cr |
| Other Income | ₹13.3 Cr | ₹10.59 Cr | ₹15.43 Cr | ₹15.93 Cr | ₹6.26 Cr | ₹9.94 Cr | ₹7.96 Cr | ₹7.77 Cr | ₹12.88 Cr | ₹7.44 Cr | ₹8.18 Cr | ₹1.89 Cr |
| Total Income | ₹250.9 Cr | ₹217.86 Cr | ₹208.95 Cr | ₹188.86 Cr | ₹243.74 Cr | ₹227.28 Cr | ₹230.66 Cr | ₹252.18 Cr | ₹229.99 Cr | ₹228.03 Cr | ₹206.94 Cr | ₹184.81 Cr |
| Cost of Materials Consumed | ₹120.95 Cr | ₹118.97 Cr | ₹112.27 Cr | ₹110.16 Cr | ₹136.94 Cr | ₹142.02 Cr | ₹153.72 Cr | ₹152.77 Cr | ₹156.47 Cr | ₹135.62 Cr | ₹117.86 Cr | ₹118.41 Cr |
| Purchases of Stock-in-Trade | ₹47.59 Lakh | ₹25 Lakh | ₹17.34 Lakh | ₹78.79 Lakh | ₹1.24 Cr | ₹1.37 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹29.93 Cr | ₹23.93 Cr | ₹20.07 Cr | -₹12.08 Cr | -₹17.24 Lakh | -₹18.6 Cr | -₹22.56 Cr | -₹2.52 Cr | -₹28.34 Cr | -₹13.68 Cr | ₹4.47 Cr | -₹6.34 Cr |
| Employee Benefit Expense | ₹19.59 Cr | ₹22.88 Cr | ₹24.05 Cr | ₹21.61 Cr | ₹22.24 Cr | ₹22.06 Cr | ₹20.69 Cr | ₹21.37 Cr | ₹17.57 Cr | ₹18.66 Cr | ₹17.19 Cr | ₹16.22 Cr |
| Finance Costs | ₹3.08 Cr | ₹3.17 Cr | ₹3.73 Cr | ₹3.26 Cr | ₹3.98 Cr | ₹3.79 Cr | ₹3.3 Cr | ₹3.47 Cr | ₹3.45 Cr | ₹3.54 Cr | ₹3.8 Cr | ₹5.55 Cr |
| Depreciation & Amortisation | ₹9.15 Cr | ₹8.97 Cr | ₹8.79 Cr | ₹8.65 Cr | ₹8.76 Cr | ₹8.61 Cr | ₹8.63 Cr | ₹8.44 Cr | ₹8.4 Cr | ₹9.27 Cr | ₹7.84 Cr | ₹7.71 Cr |
| Other Expenses | ₹37.66 Cr | ₹38.4 Cr | ₹37.64 Cr | ₹38.27 Cr | ₹42.89 Cr | ₹44.13 Cr | ₹41.27 Cr | ₹39.53 Cr | ₹42.49 Cr | ₹44.07 Cr | ₹35.53 Cr | ₹32.49 Cr |
| Total Expenses | ₹220.84 Cr | ₹216.57 Cr | ₹206.72 Cr | ₹170.66 Cr | ₹215.89 Cr | ₹203.37 Cr | ₹205.04 Cr | ₹223.08 Cr | ₹200.03 Cr | ₹197.48 Cr | ₹186.7 Cr | ₹174.03 Cr |
| Profit Before Exceptional Items & Tax | ₹30.06 Cr | ₹1.29 Cr | ₹2.23 Cr | ₹18.2 Cr | ₹27.85 Cr | ₹23.91 Cr | ₹25.63 Cr | ₹29.1 Cr | ₹29.96 Cr | ₹30.55 Cr | ₹20.24 Cr | ₹10.78 Cr |
| Exceptional Items | ₹53.92 Lakh | -₹7.11 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹30.6 Cr | -₹5.82 Cr | ₹2.23 Cr | ₹18.2 Cr | ₹27.85 Cr | ₹23.91 Cr | ₹25.63 Cr | ₹29.1 Cr | ₹29.96 Cr | ₹30.55 Cr | ₹20.24 Cr | ₹10.78 Cr |
| Total Tax Expense | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹3.23 Cr | ₹0 | ₹0 | ₹0 |
| Net Profit | ₹30.6 Cr | -₹5.82 Cr | ₹2.23 Cr | ₹18.2 Cr | ₹27.85 Cr | ₹23.91 Cr | ₹25.63 Cr | ₹29.1 Cr | ₹33.19 Cr | ₹30.55 Cr | ₹20.24 Cr | ₹10.78 Cr |
| Other Comprehensive Income | ₹88.2 Lakh | ₹56.42 Lakh | -₹39.45 Lakh | -₹15.48 Lakh | ₹1.67 Cr | -₹80.14 Lakh | -₹1.49 Cr | -₹12.44 Lakh | ₹1.6 Cr | -₹64.7 Lakh | -₹1.24 Cr | -₹5.82 Lakh |
| Total Comprehensive Income | ₹31.49 Cr | -₹5.26 Cr | ₹1.84 Cr | ₹18.04 Cr | ₹29.52 Cr | ₹23.1 Cr | ₹24.13 Cr | ₹28.98 Cr | ₹34.79 Cr | ₹29.9 Cr | ₹19.01 Cr | ₹10.72 Cr |
| EBITDA (computed) | ₹42.29 Cr | ₹13.43 Cr | ₹14.75 Cr | ₹30.11 Cr | ₹40.59 Cr | ₹36.3 Cr | ₹37.55 Cr | ₹41.02 Cr | ₹41.81 Cr | ₹43.35 Cr | ₹31.88 Cr | ₹24.03 Cr |
| Basic EPS | ₹6.03 | ₹-1.15 | ₹0.44 | ₹3.59 | ₹5.49 | ₹4.71 | ₹5.05 | ₹5.74 | ₹6.86 | ₹6.42 | ₹4.40 | ₹2.64 |
| Diluted EPS | ₹6.03 | ₹-1.15 | ₹0.44 | ₹3.59 | ₹5.49 | ₹4.71 | ₹5.05 | ₹5.74 | ₹6.86 | ₹6.42 | ₹4.40 | ₹2.64 |
Shareholding Pattern of Orchid Pharma Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 69.84%, foreign institutional investors hold 0.87%, domestic institutional investors hold 20.25%, retail and other public shareholders hold 9.05% of Orchid Pharma Limited. The company had 35,118 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% | 69.84% |
| Public | 30.16% | 30.16% | 30.16% | 30.16% | 30.16% | 30.16% |
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | |
|---|---|---|---|---|---|---|---|
| Promoters | 69.84% | 69.84% | 69.84% | 89.96% | 90.00% | 98.07% | 98.04% |
| Public | 30.16% | 30.16% | 30.16% | 10.04% | 10.01% | 1.93% | 1.97% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | -20.12 | -0.04 | -8.07 | +0.03 | - |
Board & Governance of Orchid Pharma Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Orchid Pharma Limited has 8 directors - 4 independent and 2 executive. The board is chaired by Ram Gopal Agarwal.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Ram Gopal Agarwal | Non-Executive - Non Independent Director · Chairperson | 2020-03-31 | 1 |
| Manish Dhanuka | Executive Director · MD | 2020-03-31 | 2 |
| Mridul Dhanuka | Executive Director | 2020-03-31 | 1 |
| Arjun Dhanuka | Non-Executive - Non Independent Director | 2023-10-20 | 1 |
| Dharam Vir | Non-Executive - Independent Director | 2020-06-29 | 1 |
| Manoj Kumar Goyal | Non-Executive - Independent Director | 2020-06-29 | 1 |
| Shubha Singh | Non-Executive - Independent Director | 2024-05-23 | 3 |
| Tanu Singla | Non-Executive - Independent Director | 2020-06-29 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Manoj Kumar Goyal (Chairperson), Tanu Singla, Mridul Dhanuka |
| Nomination and remuneration committee | Dharam Vir (Chairperson), Arjun Dhanuka, Manoj Kumar Goyal, Shubha Singh |
| Stakeholders Relationship Committee | Dharam Vir (Chairperson), Manoj Kumar Goyal, Tanu Singla |
| Risk Management Committee | Dharam Vir (Chairperson), Manish Dhanuka, Mridul Dhanuka, Sunil Kumar Gupta, A Chandrasekar |
| Corporate Social Responsibility Committee | Dharam Vir (Chairperson), Manish Dhanuka, Mridul Dhanuka |
| Banking Finance and Operations Committee | Manish Dhanuka (Chairperson), Mridul Dhanuka |
Group Structure of Orchid Pharma Limited
Orchid Pharma Limited has 1 subsidiary company and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Orchid Pharma Limited's business expansion strategy and organizational complexity.
| Company Name | CIN | Shares Held |
|---|---|---|
| Orchid Bio-Pharma Limited | U24230TN2022PLC150784 | - |
Showing major subsidiaries. Total: 1.
Charges & Borrowings of Orchid Pharma Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Jul 2025 | Hdfc Bank Limited | ₹142.5 Cr | Open |
| 27 Aug 2022 | Yes Bank Limited | ₹75 Cr | Open |
| 15 Nov 2021 | Hdfc Bank Limited | ₹149 Cr | Open |
| 02 Aug 2023 | Hdfc Bank Limited | ₹50 Cr | Satisfied |
| 06 Jul 2020 | Others | ₹229.67 Cr | Satisfied |
Total charge records: 179 View all charges
Employees and EPFO Compliance at Orchid Pharma Limited
Orchid Pharma Limited has a workforce of 1,101 employees as of Nov 28, 2025.
Employee Count & EPFO Data of Orchid Pharma Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Orchid Pharma Limited
GSTIN & GST Filing Data of Orchid Pharma Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Orchid Pharma Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Orchid Pharma Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Orchid Pharma Limited
MSME Payment Delays by Orchid Pharma Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Orchid Pharma Limited
Subsidiaries & Group Companies of Orchid Pharma Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Orchid Pharma Limited with ownership details.
MCA Filings & Documents of Orchid Pharma Limited
MCA Filings & Documents of Orchid Pharma Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Orchid Pharma Limited
Recent News on Orchid Pharma Limited
Frequently Asked Questions about Orchid Pharma Limited
Orchid Pharma Limited is an active public limited company in the pharma sector based in Chengalpattu, Tamil Nadu, India. It was incorporated on 01 July 1992 (34+ years old) and is registered under CIN L24222TN1992PLC022994. Listed on BSE: 524372 and NSE: BE : ORCHPHARMA. The company has 1,101 employees.
Orchid Pharma Limited reported revenue of ₹949.4 Cr for FY 2025 (up 12.00% YoY).
The current directors of Orchid Pharma Limited are:
- Mridul Dhanuka
- Arjun Dhanuka
- Tanu Singla
- Dharam Vir
- Manish Dhanuka
- Sunil Kumar Gupta
- Shubha Singh
- Ram Gopal Agarwal
- Kapil Dayya
- Manoj Kumar Goyal
The primary industry of Orchid Pharma Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Orchid Pharma Limited is listed on both BSE (code: 524372) and NSE (symbol: BE : ORCHPHARMA).
Orchid Pharma Limited can be reached at the registered office: Plot No 121 – 128 128A – 133 138 – 151 159 – 164, Sidco Industrial Estate Alathur Chengalpattu, Tamil Nadu, India – 603110, or through the website orchidpharma.com.